The xT CDx is an FDA-approved tumor profiling platform designed for solid tumor malignancies. This cutting-edge system employs a 648-gene panel to conduct DNA sequencing of solid tumors, matched to normal tissue samples such as blood or saliva. It provides detailed insight into single nucleotide variations, multi-nucleotide variants, insertions, deletions, and microsatellite instability statuses. In addition to aiding in identifying therapy candidates, it offers comprehensive tumor mutation profiling in alignment with professional oncology guidelines. A single-site assay executed at Tempus Labs, xT CDx is pivotal for ensuring personalized cancer treatment by aligning genomic data with therapeutic selections.
